6 Reasons Why You Must Attend This Event!*

  1. Hear directly from decision making Payers & HTAs about current and emerging market access requirements
  2. Benchmark your therapy’s market access strategy whether it’s via HTA Evaluation, Managed Entry or Innovative Pricing & Reimbursement Agreements.
  3. Practice makes perfect - Use our Mock Payer Panels to sharpen your products’ value arguments in front of REAL PAYERS!
  4. Learn something new! With our fresh speaker lineup, you’ll hear current, relevant case studies based on actual market access experiences.
  5. Networking: Make real contact through our unrivalled networking with senior-level industry peers, payers & stakeholders and expert consultancies.
  6. Join the dialogue and have your questions answered during open and interactive panel discussions with senior pharma industry and payer representatives to gain critical insights.

*Only for those looking to improve their Specialty products’ market access.

Request agenda here for complete speaker list

Payers & HTA Agencies

Head of the Division of Medicines and Remedies
GKV – Spitzenverband, Germany

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Senior Scientific Adviser
NICE - National Institute for Health and Care, UK

Head of Section, Health Economics
Amgros, Pharmaceutical Procurement Service for Regional Authorities, Denmark

Associate Professor, Economic Evaluations in Health Care, Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)
, Erasmus University Rotterdam, Netherlands

Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy

Member
Impact HTA

Head of Clinical Engineering Service
Humanitas Research Hospital, Italy

Member, Joint Committee Vaccination & Immunisation (JCVI) London, UK
Prof. of Pharmacoeconomics, University of Groningen, The Netherlands

 

Industry Experts

Head of Program Realization, Global Market Access
Takeda Pharmaceuticals, Switzerland

Global Head Market Access
Roche, Switzerland

Vice President, Head of Global Payor Marketing, Sales and Relations
Sandoz Biopharmaceuticals

Vice President, Pricing & Market Access Europe
Teva Specialty Medicines, Netherlands

Senior Director, Market Access
Roche Tissue Diagnostics, USA

International Personalised Reimbursement Model Leader
F. Hoffmann-La Roche, Switzerland

Senior International Health Policy Leader
F. Hoffmann-La Roche, Switzerland

Vice President Managed Markets
Invitae, USA

Europe Market Access and Pricing Lead PharmaEurope
GSK, UK

Market Access Director
MorphoSys, Germany

Director Government Affairs
LIF (The research based pharmaceutical industry), Sweden


 

Experienced Solution Providers

Vice President, Strategic Consulting (Life Sciences)
IBM Watson Health , USA

Principal Consultant
Huron Consulting Group, UK

Principal Consultant
Huron Consulting Group, UK

Senior Consultant
Huron Consulting Group, UK

Managing Director,
Valid Insight, UK

Request agenda here for complete speaker list

Pictures from recent PharmAccess Leaders Forum. Imagine being there...

“Payers” (health plans, sick funds & insurers, payers, health technology assessors, hospital financial management & health department officials) in almost all circumstances, in both developed and developing countries are under extreme budgetary pressure. Many health systems in the developed world, face ageing populations, economic crisis and rapidly increasing healthcare costs in general, including the sustained cost increases of innovative and novel drugs. This is forcing payers to make difficult choices regarding which medical procedures & medications to fund and reimburse. No longer are “me too” drugs that have achieved regulatory approval simply approved for reimbursement at high prices. Payers need to make tough decisions based on what they define as “value”, unfortunately sometimes at the expense of funding treatments in some “lower priority” disease indications or individual patients. Despite intense political pressure from patients and stakeholders who believe healthcare is an inalienable “right” and should be “free for all,” the reality is that payers have a finite and limited budget, and face a high degree of risk in decision making. They operate within an environment where a multitude of products are on offer, each making various therapeutic claims of efficacy and safety, often with insufficient data to validate supposed health outcome improvements over existing treatment options. How can payers make the right decision in a high-risk, high uncertainty environment?

Various options and decision-making tools exist, some old, some novel. Traditional decision making based on, for example, price referencing, DRGs budgets or generic substitution are still significant. However, recent advances in the sophistication of HTA analysis and modeling, flexible pay for performance models, risk-sharing and value-based pricing schemes have become increasingly important to mitigate payer risk and allocate financial resources to the areas of pressing need. Savings and outcome improvements can also be found through finding efficiency gains at the healthcare delivery level, providing the right incentives for prescribers and improving patient adherence.

Why this meeting?

This meeting will provide an ideal opportunity for “payers” and other decision makers from both public and private organisations, to benchmark with peers internationally and provide pharma companies an invaluable insight into the decision-making processes and approaches of these vital stakeholders. Attendees will be able to understand and develop best practice approaches to such vital and common challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications.

SPEAKER LIST - DAY 1

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Senior Scientific Adviser
NICE - National Institute for Health and Care, UK

Head of Section, Health Economics
Amgros, Pharmaceutical Procurement Service for Regional Authorities, Denmark

Vice President, Strategic Consulting (Life Sciences)
IBM Watson Health, USA

Head of the Division of Medicines and Remedies
GKV – Spitzenverband, Germany

Member
Impact HTA

Associate Professor, Economic Evaluations in Health Care, Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)
, Erasmus University Rotterdam, Netherlands

Principal Consultant
Huron Consulting Group, UK

Vice President, Pricing & Market Access Europe
Teva Specialty Medicines, Netherlands

 

As the product nature of precision medicines and companion diagnostics becomes increasingly complex, so too is the market access process surrounding these essential tests and procedures. These diagnostics bring unique market access & procurement challenged through DRG coding, bundling and procurement for laboratory test service providers. As the cost of these tests increases, so too does the requirement to justify the value and ROI to all necessary stakeholders. For In-Vitro diagnostics, partnering and strategic alliances with pharma (if not already vertically integrated) provides a strong market access vector, but achieving this has been proven difficult with only a handful of successful examples to date. As payers, procurers, HMOs and purchasers demand more evidence to justify costs, the challenges surrounding market access have never been greater. This one-day stream will discuss the market access challenges affecting personalised medicine and In-Vitro diagnostics globally with case studies of successful launches and cautionary tales of those which were not, to provide benchmarking and learning opportunities for all participants.

SPEAKER LIST - DAY 2 - STREAM 1

Global Head Market Access
Roche, Switzerland

International Personalised Reimbursement Model Leader
F. Hoffmann-La Roche, Switzerland

Senior International Health Policy Leader
F. Hoffmann-La Roche, Switzerland

Vice President Managed Markets
Invitae, USA

Senior Director, Market Access
Roche Tissue Diagnostics, USA

Member, Joint Committee Vaccination & Immunisation (JCVI) London, UK
Prof. of Pharmacoeconomics, University of Groningen, The Netherlands

Europe Market Access and Pricing Lead PharmaEurope
GSK, UK

 

Flexible pricing and reimbursement schemes, have been in existence for around a decade in Europe and places like Canada, and is starting to become popular in the USA. They are known by many other names including Managed Entry Agreements (MEAs), Value-Based Pricing, Pay for Performance or Outcomes-based schemes. Most agreements so far, in reality, have been more basic financial-based arrangements (such as budget-capping and refunds for payers), rather than more sophisticated value-based models, based on improved health outcomes. As ‘’patient-centricity” becomes more of a focus for pharmaceutical companies and payers alike, most would agree that in principle, paying for outcomes is ideal and a “win-win” for all stakeholders, especially the patient. In theory, this helps payers conditionally approve the reimbursement of an innovative, yet expensive therapy and allow patient access without delay. Quality evidence is very much lacking at the time of launch, so the “wait and see approach” that risk sharing can provide, can be a great compromise for the industry, payers and patients. Payers can also avoid wastage when drugs are unsuccessful, but only paying for positive outcomes. The pharmaceutical industry can benefit, by maintaining a higher list price to avoid the negative price spiral due to reference pricing. They can also benefit from early-access. There have been also some high-profile value-based pricing schemes in the USA, which will pay for outcomes and look very innovative and promising. On both sides of the Atlantic, innovative agreements are here to stay. However, implementing complex outcomes-based schemes in practice is very challenging. It is difficult enough to measure outcomes across a patient population, let alone individual patients. Electronic Medical Records are still not widespread or integrated enough to provide sufficient real-world data, so busy doctors have to still keep records the manual way, which are prone to error. This stream will clarify the process of establishing, preparing, implementing and delivering a successful risk-sharing / managed entry agreement s, outcome based and value-based schemes, to improve the access of innovative medicines for patients.

SPEAKER LIST - DAY 2 - STREAM 2

Head of Program Realization, Global Market Access
Takeda Pharmaceuticals, Switzerland

Market Access Director
MorphoSys, Germany

Director Government Affairs
LIF (The research based pharmaceutical industry), Sweden

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Associate Professor, Economic Evaluations in Health Care
Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)

Erasmus University Rotterdam, Netherlands

Member
Impact HTA

Senior International Health Policy Leader
F. Hoffmann-La Roche, Switzerland

Principal Consultant
Huron Consulting Group, UK

Principal Consultant
Huron Consulting Group, UK

Senior Consultant
Huron Consulting Group, UK

Payers, HTAs & Policy Makers:
Senior representatives from Payers, health plans & insurers, Public health experts, health technology assessors, hospital financial management, government & health ministry officials, health management and managed care organizations, epidemiology, horizon scanning, scientific advice, pharmacy strategy & budget management.

Industry: Corporate senior management, vice presidents, directors, senior managers in:
Market access, health economics, pricing & reimbursement, health outcomes, government & regulatory affairs as well as those focused on designing studies to achieve value-adding endpoints, such as R&D strategy, clinical development and medical affairs.

Other Stakeholders:
Regulatory agencies, key-opinion leaders, independent health economists, health researchers and academics, physicians, patient groups, consultants & solution providers

The PharmAccess Leaders Forum will also have the MedTech Access Leaders Forum co-located. That event is for senior directors of Market Access at MedTech & Diagnostic manufacturers and will have a market access approach-specific streams for HTA Evaluation or Procurement & Tendering. There is also additional focus given to Surgical/implantable products and In-Vitro Diagnostics to be used in tandem with Precision Medicine therapies. It will also feature a Mock Payer Panel Workshop with Real Payers giving feedback to participants. For more information click the banner below:

Event Partners

Media Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Share with Colleagues